James Gordon, MD
Ophthalmology · Armonk, NYNPI 1497797641
Payments from drug & device makers
Across 444 payments — averaging $20.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$3K
- Kala Pharmaceuticals, Inc.$1K
- AbbVie$968
- Novartis$656
- Amgen$586
- Sun Pharmaceutical Industries Inc.$549
- plus $3K from 25 others
What the payments were for
- Food & beverage$9,21099%
- Education$1001%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 119 | $2,534 |
| Kala Pharmaceuticals, Inc. | 58 | $1,251 |
| AbbVie(2 entities) | 48 | $968 |
| Novartis | 46 | $656 |
| Amgen(2 entities) | 34 | $586 |
| Sun Pharmaceutical Industries Inc. | 28 | $549 |
| Aerie Pharmaceuticals, Inc. | 9 | $290 |
| Oyster Point Pharma, Inc. | 15 | $282 |
| Bausch & Lomb Americas Inc. | 14 | $253 |
| Harrow Eye, LLC | 14 | $234 |
| Mallinckrodt Hospital Products Inc. | 6 | $219 |
| Eyepoint US, Inc. | 10 | $203 |
| Rxsight Inc | 3 | $193 |
| NEW World Medical,inc. | 1 | $150 |
| Alimera Sciences, Inc. | 7 | $136 |
| Tarsus Pharmaceuticals, Inc. | 4 | $122 |
| Beaver-visitec International, Inc. | 1 | $122 |
| Dompe US, Inc. | 4 | $94 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $92 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $56 |
| Biotissue Holdings Inc. | 2 | $53 |
| Sight Sciences, Inc. | 2 | $50 |
| Shire North American Group Inc | 2 | $46 |
| Sanofi | 3 | $41 |
| Rayner Intraocular Lenses Limited | 1 | $26 |
| Eyevance Pharmaceuticals LLC | 1 | $25 |
| Baudax Bio Inc. | 1 | $23 |
| Boston Scientific | 1 | $19 |
| Ocular Therapeutix, Inc. | 1 | $14 |
| Alcon Research LLC | 1 | $12 |
| Spark Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,310 in reported general payments places this provider in the 85th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 39 | $34,754 |
| XiidraLifitegrast | 20 | $21,137 |
| CequaCyclosporine | 16 | $16,710 |
| EysuvisLoteprednol Etabonate | 28 | $13,637 |
| Restasis MultidoseCyclosporine | 16 | $11,023 |
| TyrvayaVarenicline Tartrate | 16 | $10,250 |
| LumiganBimatoprost | 18 | $8,258 |
| Prednisolone Acetate | 86 | $2,863 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 14 | $2,775 |
| Doxycycline Hyclate | 88 | $1,848 |
| Latanoprost | 101 | $1,459 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 117 | $1,227 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 12 | $678 |
| Ofloxacin | 47 | $522 |
| Ketorolac Tromethamine | 21 | $379 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Restasis Multidose, Lumigan | $968 | $54,03573 claims |
| Bausch & Lomb Americas Inc.Xiidra | $253 | $21,13720 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $549 | $16,71016 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $1,251 | $13,63728 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $282 | $10,25016 claims |
| AlconSimbrinza | $2,534 | $2,77514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in Armonk
- Douglas JabsNew York$24.3M
- David RubaltelliBrooklyn$8.9M
- Philip FerroneGreat Neck$5.8M
- Eric DonnenfeldGarden City$2.6M
- Nathan RadcliffeNew York$2.4M
- Glenn StollerRockville Centre$2.1M
- Richard SpaideNew York$1.7M
- Paul HartmanRochester$1.6M
- Jason SlakterNew York$1.2M
- David ChuNew York$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.